26 documents found, page 1 of 3
An HIV-1/HIV-2 chimeric envelope glycoprotein generates binding and neutralisin...
Taveira, Nuno; Figueiredo, Inês; Calado, Rita; Martin, Francisco; Bártolo, Inês; Marcelino, José M.; Borrego, Pedro; Cardoso, Fernando; Barroso, HelenaThe development of immunogens that elicit broadly reactive neutralising antibodies (bNAbs) is the highest priority for an HIV vaccine. We have shown that a prime-boost vaccination strategy with vaccinia virus expressing the envelope glycoprotein gp120 of HIV-2 and a polypeptide comprising the envelope regions C2, V3 and C3 elicits bNAbs against HIV-2. We hypothesised that a chimeric envelope gp120 containing th...
An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralisin...
Taveira, Nuno; Figueiredo, Inês; Calado, Rita; Martin, Francisco; Bártolo, Inês; Marcelino, José Maria; Borrego, Pedro; Cardoso, Fernando M HThe development of immunogens that elicit broadly reactive neutralising antibodies (bNAbs) is the highest priority for an HIV vaccine. We have shown that a prime-boost vaccination strategy with vaccinia virus expressing the envelope glycoprotein gp120 of HIV-2 and a polypeptide comprising the envelope regions C2, V3 and C3 elicits bNAbs against HIV-2. We hypothesised that a chimeric envelope gp120 containing th...
An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralisin...
Taveira, Nuno; Figueiredo, Inês; Calado, Rita; Martin, Francisco; Bártolo, Inês; Marcelino, José M.; Borrego, Pedro; Cardoso, Fernando M HThe development of immunogens that elicit broadly reactive neutralising antibodies (bNAbs) is the highest priority for an HIV vaccine. We have shown that a prime-boost vaccination strategy with vaccinia virus expressing the envelope glycoprotein gp120 of HIV-2 and a polypeptide comprising the envelope regions C2, V3 and C3 elicits bNAbs against HIV-2. We hypothesised that a chimeric envelope gp120 containing th...
Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isola...
Martin, Francisco; Marcelino, José Maria; Palladino, Claudia; Bártolo, Inês; Tracana, Susana; Moranguinho, Inês; Gonçalves, Paloma; Mateus, RitaA minority of HIV-1-infected patients produce broadly neutralizing antibodies (bNAbs). Identification of viral and host correlates of bNAb production may help develop vaccines. We aimed to characterize the neutralizing response and viral and host-associated factors in Angola, which has one of the oldest, most dynamic, and most diverse HIV-1 epidemics in the world. Three hundred twenty-two HIV-1- infected adults...
Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isola...
Martin, Francisco; Marcelino, José Maria; Palladino, Claudia; Bártolo, Inês; Tracana, Susana; Moranguinho, Inês; Gonçalves, Paloma; Mateus, RitaA minority of HIV-1-infected patients produce broadly neutralizing antibodies (bNAbs). Identification of viral and host correlates of bNAb production may help develop vaccines. We aimed to characterize the neutralizing response and viral and host-associated factors in Angola, which has one of the oldest, most dynamic, and most diverse HIV-1 epidemics in the world. Three hundred twenty-two HIV-1-infected adults ...
Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isola...
Martin, Francisco; Marcelino, José Maria; Palladino, Claudia; Bártolo, Inês; Tracana, Susana; Moranguinho, Inês; Gonçalves, Paloma; Mateus, RitaA minority of HIV-1-infected patients produce broadly neutralizing antibodies (bNAbs). Identification of viral and host correlates of bNAb production may help develop vaccines. We aimed to characterize the neutralizing response and viral and host-associated factors in Angola, which has one of the oldest, most dynamic, and most diverse HIV-1 epidemics in the world. Three hundred twenty-two HIV-1-infected adults ...
Long-term and low-level envelope C2V3 stimulation by highly diverse virus isola...
Martin, Francisco; Marcelino, José Maria; Palladino, Claudia; Bártolo, Inês; Tracana, Susana; Moranguinho, Inês; Gonçalves, Paloma; Mateus, RitaA minority of HIV-1-infected patients produce broadly neutralizing antibodies (bNAbs). Identification of viral and host correlates of bNAb production may help develop vaccines. We aimed to characterize the neutralizing response and viral and host-associated factors in Angola, which has one of the oldest, most dynamic, and most diverse HIV-1 epidemics in the world. Three hundred twenty-two HIV-1-infected adults ...
Increased antibacterial properties of indoline-derived phenolic Mannich bases
Rimpiläinen, Tatu; Nunes, Alexandra; Calado, Rita; Fernandes, Ana S.; Andrade, Joana; Ntungwe, Epole; Spengler, Gabriella; Szemerédi, NikolettaThe search for antibacterial agents for the combat of nosocomial infections is a timely problem, as antibiotic-resistant bacteria continue to thrive. The effect of indoline substituents on the antibacterial properties of aminoalkylphenols was studied, leading to the development of a library of compounds with minimum inhibitory concentrations (MICs) as low as 1.18 μM. Two novel aminoalkylphenols were identified ...
A prime-boost immunization strategy with vaccinia virus expressing novel gp120 ...
Calado, Rita; Duarte, Joana; Borrego, Pedro; Marcelino, José Maria; Bártolo, Inês; Martin, Francisco; Figueiredo, Inês; Almeida, Silvia; Luís, GraçaDevelopment of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority for the HIV-1 vaccine field. Envelope glycoproteins from non-B-non-C HIV-1clades have not been fully explored as components of a vaccine. We produced Vaccinia viruses expressing a truncated version of gp120 (gp120t) from HIV-1 clades CRF02_AG, H, J, B, and C and examined their immunogenicity in mice and rabbits. M...
A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 ...
Calado, Rita; Duarte, Joana; Borrego, Pedro; Marcelino, José Maria; Bártolo, Inês; Martin, Francisco; Figueiredo, Inês; Almeida, Sílvia; Graça, LuisDevelopment of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority for the HIV-1 vaccine field. Envelope glycoproteins from non-B-non-C HIV-1clades have not been fully explored as components of a vaccine. We produced Vaccinia viruses expressing a truncated version of gp120 (gp120t) from HIV-1 clades CRF02_AG, H, J, B, and C and examined their immunogenicity in mice and rabbits. M...